GeoVax to Present at the Emerging Growth Conference on August 21, 2024
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the
BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
公司將討論Mpox的最新發展以及與之相關的里程碑
BARDA 下一代 COVID-19 疫苗獲得 NextGen 項目獎
ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held August 21-22, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman and CEO, David Dodd, in real time.
喬治亞州亞特蘭大,2024年8月15日(GLOBE NEWSWIRE)——開發癌症和傳染病免疫療法和疫苗的生物技術公司GeoVax Labs, Inc.(納斯達克股票代碼:GOVX)很高興地宣佈,它已受邀出席2024年8月21日至22日舉行的下一屆新興增長會議。這項實時互動的在線活動將使現有股東和投資界有機會與公司董事長兼首席執行官戴維·多德進行實時互動。
Mr. Dodd will be presenting at 4:10pm ET on Wednesday, August 21, 2024. Following his presentation, Mr. Dodd will open the floor for questions, time permitting. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Dodd will do his best to get through as many of them as possible. Please register here to ensure you are able to attend the conference and receive any updates that are released. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, .
多德先生將於美國東部時間2024年8月21日星期三下午4點10分發表演講。如果時間允許,多德先生將在發言後開始提問。請提前將您的問題提交到 Questions@EmergingGrowth.com 或在活動期間提問,多德先生將盡力盡可能多地解答問題。請在此處註冊,以確保您能夠參加會議並接收發布的所有更新。如果與會者無法在會議當天直播參加活動,則還將在EmergingGrowth.com和新興增長YouTube頻道上提供存檔的網絡直播。
About the Emerging Growth Conference
關於新興增長會議
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community. The conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions are conducted through video webcasts and take place in the Eastern time zone.
新興增長會議是上市公司向投資界展示和傳達其新產品、服務和其他重要公告的有效途徑。會議的重點和覆蓋範圍包括各個成長領域的公司,擁有強大的管理團隊、創新的產品和服務、有針對性的戰略、執行以及長期增長的整體潛力。其受衆可能包括成千上萬的個人和機構投資者,以及投資顧問和分析師。所有會議均通過視頻網絡廣播進行,並在東部時區舉行。
About GeoVax
關於 GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: .
GeoVax Labs, Inc. 是一家臨床階段的生物技術公司,爲世界上許多最具威脅性的傳染病開發新疫苗和實體瘤癌療法。該公司的主要臨床項目是 GEO-CM04S1,這是一種下一代 COVID-19 疫苗,GeoVax最近獲得了一份由巴爾達資助的合同,贊助一項由10,000名參與者的20期臨床試驗,該試驗旨在評估 GEO-CM04S1 與已批准的 COVID-19 疫苗相比的療效。此外,GEO-CM04S1 目前正在進行三項二期臨床試驗,被評估爲(1)免疫功能低下患者(例如血液系統癌症患者和當前授權的 COVID-19 疫苗不足的其他患者群體)的主要疫苗;(2)慢性淋巴細胞白血病(CLL)患者的加強疫苗;(3)在之前接種過 mRNA 疫苗的健康患者中,這是一種更強大、更耐用的 COVID-19 增強疫苗。在腫瘤學領域,主要臨床項目正在一項針對晚期頭頸癌的多中心1/2期臨床試驗中評估一種新的溶瘤實體瘤基因導向療法Gedeptin。GeoVax擁有強大的知識產權組合來支持其技術和候選產品,並擁有其技術和產品的全球版權。該公司擁有一支領導團隊,在過去的幾十年中,他們推動了多家生命科學公司的重大價值創造。有關我們臨床試驗現狀和其他更新的更多信息, 訪問我們的網站:.
Company Contact: | Investor Relations Contact: | Media Contact: | ||
info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
678-384-7220 | 212-698-8696 | 202-779-0929 |
公司聯繫人: | 投資者關係聯繫人: | 媒體聯繫人: | ||
info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
678-384-7220 | 212-698-8696 | 202-779-0929 |